Human leukocyte antigen-DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients

Transplant Infectious Disease

Volumn 6, Issue 4, 2004, Pages 147-155

  Hoffman, Jill A ^a,c   Weinberg, K I ^b   Azen, C G ^b   Horn, M V ^b   Dukes, L ^b   Starnes, V A ^b   Woo, M S ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Lung transplantation; Monocyte HLA DR expression; Pneumonia

Indexed keywords

CD14 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LIVING DONOR; LUNG TRANSPLANTATION; MALE; MEASUREMENT; MONOCYTE; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; SURGICAL PATIENT;

ADOLESCENT; CHILD; DISEASE SUSCEPTIBILITY; FEMALE; GENE EXPRESSION; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-10; LUNG TRANSPLANTATION; MALE; MONOCYTES; PNEUMONIA; RISK FACTORS; TIME FACTORS;

EID: 17144379985     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2004.00069.x     Document Type: Article

References (52)

1. Woo MS, MACLAUGHLIN EF, HORN MV, et al. Living donor lung transplantation: the pediatric experience. Pediatr Transpl 1998: 3: 185-190.
2. BARR ML, BAKER CJ, SCHENKEL FA, et al. Living donor lung transplantation: selection, technique and outcome. Transpl Proc 2001: 33: 3527-3532.
3. LINSANGAN LC, HOFFMAN JA, MASON WH, et al. Infectious complications in pediatric lung and heart-lung-transplantation. Abstract # J-174, slide presentation, Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 1997. Manuscript in preparation.
4. ALEXANDER BD, TAPSON VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001: 3: 128-137.
5. STARNES VA, WOO MS, MACLAUGHLIN EFG, et al. Comparisons of outcomes between living donor and cadaveric lung transplantation in children. Ann Thorac Surg 1999: 68: 2279-2284.
6. WOO MS, MACLAUGHLIN EF, HORN MV, SZMUSZKOVICZ JR, BARR ML, STARNES VA. Bronchiolitis obliterans is not the primary cause of death in pediatric living donor lobar lung transplant recipients. J Heart Lung Transplant 2001: 20: 491-496.
7. LIPUMA JJ. Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis? Transpl Infect Dis 2001: 3: 149-160.
8. GORDON SM, AVERY RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001: 3: 161-167.
9. LIVINGSTON DH, APPEL SH, WELLHAUSEN SR, SONNENFELD L, POLK HC JR. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 1988: 123: 1309-1311.
10. HERSHMAN MJ, CHEADLE WG, WELLHAUSEN SR, DAVIDSON PF, POLK HC JR. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990: 77: 204-207.
11. CHEADLE WG, HERSHMAN MJ, WELLHAUSEN SR, POLK HC JR. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 1991: 161: 639-645.
12. WAKEFIELD CH, CAREY PD, FOULDS S, MONSON JRT, GUILLOU PJ. Changes in major histocompatibility complex class II expression in monocytes and Tcells of patients developing infection after surgery. Br J Surg 1993: 80: 205-209.
13. GIANNOUDIS PV, SMITH RM, PERRY SL, WINDSOR AJ, DICKSON RA, BELLAMY MC. Immediate IL-10 expression following major orthopaedic trauma: relationship to antiinflammatory response and subsequent development of sepsis. Intensive Care Med 2000: 26: 1076-1081.
14. TSCHAIKOWSKY K, HEDWIG-GEISSING M, SCHIELE A, BREMER F, SCHYWALSKY M, SCHÜTTLER J. Coincidence of pro- and antiinflammatory responses in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002: 30: 1015-1023.
15. FUMEAUX T, PUGIN J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002: 166: 1475-1482.
16. VOLK HD, REINKE P, FALCK P, STAFFA G, BRIEDIGKEIT H, BAEHR R. Diagnostic value of an immune monitoring program for the clinical management of immunosuppressed patients with septic complications. Clin Transplant 1989: 3: 246-252.
17. REINKE P, PROSCH S, KERN F, VOLK H-D. Mechanisms of human cytomegalovirus (HCMV) (re) activation and its impact on organ transplant patients. Transpl Infect Dis 1999: 1: 157-164.
18. VAN DEN BERK JMM, OLDENBURGER RHJ, VAN DEN BERG AP, et al. Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. Transplantation 1997: 63: 1846-1848.
19. HAVEMAN JW, VAN DEN BERG AP, VAN DEN BERK JMM, et al. Low HLA-DR expression on peripheral blood monocytes predicts bacterial sepsis after liver transplantation: relation with prednisolone intake. Transpl Infect Dis 1999: 1: 146-152.
20. ALLEN ML, PETERS MJ, GOLDMAN L, et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med 2002: 30: 1140-1145.
21. VOLK HD, GRUNER S, FALCK P, VON BAEHR R. The influence of interferon-gamma and various phagocytic stimuli on the expression of MHC-class II antigens on human monocytes - relation to the generation of reactive oxygen intermediates. Immunol Lett 1986: 13: 209-214.
22. SPELLBERG B, EDWARDS JE JR. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001: 32: 76-102.
23. KOPPELMAN B, NEEFJES JJ, DE VRIES JE, DE WALL MALEFY R. Interleukin-10 down-regulates MHC class II αβ peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997: 7: 861-871.
24. WOLK K, DÖCKE W-D, VON BAEHR V, VOLK H-D, SABAT R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000: 96: 218-223.
25. WOLK K, KUNZ S, CROMPTON NEA, VOLK H-D, SABAT R. Multiple mechanisms of reduced major histocompatibility complex Class II expression in endotoxin tolerance. J Biol Chem 2003: 278: 18030-18036.
26. DE WAAL MALEFYT R, ABRAMS J, BENNETT B, FIGDOR CG, DE VRIES JE. Interleukin 10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991: 174: 1209-1220.
27. BAUER J, LANGUE A, FRANZKE A, GARCIA C, VON BOEHMER, SARUKHAN A. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J Exp Med 1998: 187: 177-183.
28. CONTI P, KEMPURAJ D, KANDERE K, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003: 86: 123-129.
29. KLAVA A, WINDSOR A, FARMERY S, et al. Interleukin-10: a role in the development of postoperative immunosuppression. Arch Surg 1997: 132: 425-429.
30. HYNNINEN M, PETTILÄ V, TAKKUNEN O, et al. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 2003: 20: 1-4.
31. KAWASAKI T, OGATA M, KAWASAKI C, TOMIHISA T, OKAMOTO K, SHIGEMATSU A. Surgical stress induces endotoxin hyporesponsiveness and an early decrease of monocyte mCD14 and HLA-DR expression during surgery. Anesth Analg 2001: 92: 1322-1326.
32. HENSLER T, HECKER H, HEEG K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun 1997: 65: 2283-2291.
33. PERRY S, MOSTAFA SM, WENSTONE R, SHENKIN A, MCLAUGHLIN PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 2003: 29: 1245-1252.
34. GROUX H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 2003: 75: 8S-12S.
35. JONULEIT H, ADEMA G, SCHMITT E. Immune regulation by regulatory T cells: implications for transplantation. Transplant Immunol 2003: 11: 267-276.
36. ROILIDES E, SEIN T, RODEN M, SCHAUFELE RL, WALSH TJ. Elevated serum concentrations of IL-10 in nonneutropenic patients with invasive aspergillosis. J Infect Dis 2001: 183: 518-520.
37. CLEMONS KV, GRUNIG G, SOBEL RA, MIRELS LF, RENNICK DM, STEVENS DA. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 knockout mice to lethal systemic aspergillosis. Clin Exp Immunol 2000: 122: 186-191.
38. CHMIEL JF, BERGER M, KONSTAN MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002: 23: 5-27.
39. BONFIELD TL, KONSTAN MW, BERGER M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999: 104: 72-78.
40. BONFIELD TL, KONSTAN MW, BURFEIND P, et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995: 13: 257-261.
41. SOLTYS J, BONFIELD T, CHMIEL J, BERGER M. Functional IL-10 deficiency in the lung of cystic fibrosis (cftr -/-) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol 2002: 168: 1903-1910.
42. MOSS RB, BOCIAN RC, HSU YP, et al. Reduced IL-10 secretion by CD4 T lymphocytes expressing mutant CFTR. Clin Exp Immunol 1996: 106: 374-388.
43. MOSS RB, HSU YP, OLDS L. Cytokine dysregulation in activated cystic fibrosis peripheral lymphocytes. Clin Exp Immunol 2000: 120: 518-525.
44. JOHANSEN HK, HOUGAN HP, RYGAARD J, HOIBY N. Interferon-gamma treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats. Clin Exp Immunol 1996: 103: 212-218.
45. JOHANSEN HK, CRYZ SJ, HOUGEN HP, MOSER C, HOIBY N. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia: a new prophylactic principle. Behring Inst Mitt 1997: 98: 269-273.
46. POLK HC JR, CHEADLE WG, LIVINGSTON DH, et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 1992: 163: 191-196.
47. DRIES DJ, JURKOVICH GJ, MAIER RV, et al. Effect of interferon gamma on infection-related deaths in patients with severe injuries. A randomized, double blind, placebo-controlled trial. Arch Surg 1994: 129: 1031-1041.
48. KOX WJ, BONE RC, KRAUSCH D, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 1997: 157: 389-393.
49. DOCKE W-D, RANDOW F, SYRGE U, et al. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment. Nat Med 1997: 3: 678-681.
50. NIERHAUS A, MONTAG B, TIMMLER N, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003: 29: 646-651.
51. DENZEL C, RIESE J, HOHENBERGER W, et al. Monitoring of immunotherapy by measuring monocyte HLA-DR expression and stimulated TNFα production during sepsis after liver transplantation. Intensive Care Med 1998:24: 1343-1344.
52. SAFDAR A, RODRIGUEZ G, OHMAGARI N, CHAMPLIN RE. Safety of recombinant interferon-gamma adjuvant therapy for invasive fungal infections in the recipients of hematopoietic stem cell transplantation. Abstract #36, poster presentation, 13th International Symposium on Infections in the Immunocompromised Host, Granada Spain, June, 2004.